On Friday, Moderna Inc. (NASDAQ:MRNA) announced that it has submitted an FDA application for review of its Spikevax 2024-2025 formula, which targets the SARS-CoV-2 variant JN.1. The submission is based on FDA guidance, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 composition for the 2024-2025 season. JN.1 and its descendants KP.2 and KP.3 are the versions of the virus that are most common in the U.S. right now, according to the US Centers for Disease Control and Prevention. In its briefing document, ...